Advaxis Stock Price, News & Analysis (NASDAQ:ADXS)

$1.89 +0.09 (+5.00 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$1.89
Today's Range$1.80 - $1.99
52-Week Range$1.80 - $10.06
Volume2.16 million shs
Average Volume1.16 million shs
Market Capitalization$78.52 million
P/E Ratio-0.82
Dividend YieldN/A
Beta0.7

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ADXS
CUSIPN/A
Phone+1-732-5451590

Debt

Debt-to-Equity RatioN/A
Current Ratio3.89%
Quick Ratio3.89%

Price-To-Earnings

Trailing P/E Ratio-0.821739130434783
Forward P/E Ratio-0.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.03 million
Price / Sales8.05
Cash FlowN/A
Price / CashN/A
Book Value$1.32 per share
Price / Book1.43

Profitability

Trailing EPS($2.30)
Net Income$-93,430,000.00
Net Margins-776.63%
Return on Equity-114.00%
Return on Assets-75.59%

Miscellaneous

Employees108
Outstanding Shares51,210,000

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Wednesday, December, 20th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.02. The biotechnology company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $3.05 million. Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. View Advaxis' Earnings History.

When will Advaxis make its next earnings announcement?

Advaxis is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Advaxis.

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2018?

2 brokerages have issued 12-month target prices for Advaxis' stock. Their forecasts range from $19.00 to $23.00. On average, they anticipate Advaxis' share price to reach $21.00 in the next year. View Analyst Ratings for Advaxis.

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:

  • David Sidransky M.D., Independent chairman of the Board (Age 57)
  • Anthony Lombardo, Interim Chief Executive Officer (Age 70)
  • Sara M. Bonstein, Chief Financial Officer, Executive Vice President (Age 37)
  • Robert G. Petit Ph.D., Executive Vice President, Chief Scientific Officer (Age 58)
  • James P. Patton M.D., Independent Non-Executive Vice Chairman of the Board (Age 60)
  • Roni A. Appel, Independent Director (Age 51)
  • Richard J. Berman J.D., Independent Director (Age 75)
  • Samir N. Khleif, Independent Director (Age 54)

Who owns Advaxis stock?

Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.49%), Renaissance Technologies LLC (1.19%), Deutsche Bank AG (1.12%), Bank of Montreal Can (1.05%), Bank of New York Mellon Corp (0.34%) and Franklin Street Advisors Inc. NC (0.31%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Who sold Advaxis stock? Who is selling Advaxis stock?

Advaxis' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and BlackRock Inc.. Company insiders that have sold Advaxis company stock in the last year include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit and Sara Bonstein. View Insider Buying and Selling for Advaxis.

Who bought Advaxis stock? Who is buying Advaxis stock?

Advaxis' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, Bank of Montreal Can, Franklin Street Advisors Inc. NC, Capital Analysts LLC, Cutler Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Advaxis.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of Advaxis stock can currently be purchased for approximately $1.89.

How big of a company is Advaxis?

Advaxis has a market capitalization of $78.52 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Advaxis employs 108 workers across the globe.

How can I contact Advaxis?

Advaxis' mailing address is 305 College Rd E, PRINCETON, NJ 08540-6608, United States. The biotechnology company can be reached via phone at +1-732-5451590 or via email at [email protected]


MarketBeat Community Rating for Advaxis (ADXS)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  305
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Advaxis (NASDAQ:ADXS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$21.00$21.00$22.00
Price Target Upside: 636.84% upside636.84% upside572.00% upside228.36% upside

Advaxis (NASDAQ:ADXS) Consensus Price Target History

Price Target History for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ:ADXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/28/2017Cantor FitzgeraldSet Price TargetBuy$19.00LowView Rating Details
12/27/2017HC WainwrightSet Price TargetBuy$23.00MediumView Rating Details
9/9/2016Jefferies GroupReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016BarclaysBoost Price TargetOverweight$15.00 -> $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Advaxis (NASDAQ:ADXS) Earnings History and Estimates Chart

Earnings by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ ADXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018($0.58)N/AView Earnings Details
12/20/2017Q4 2017($0.55)($0.57)$3.05 million$1.76 millionViewListenView Earnings Details
9/11/2017Q3($0.53)($0.80)$3.43 million$3.05 millionViewN/AView Earnings Details
6/6/2017Q2 2017($0.49)($0.51)$3.79 million$3.43 millionViewN/AView Earnings Details
3/10/2017Q1 2017($0.52)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
1/9/2017Q4 2016($0.55)$3.75 millionViewN/AView Earnings Details
9/8/2016Q3 2016($0.22)($0.48)ViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
2/26/2016Q1 2016($0.41)($0.59)$0.10 million$0.25 millionViewN/AView Earnings Details
1/8/2016Q4 2015($0.37)ViewN/AView Earnings Details
9/11/2015Q3 2015($0.31)($0.44)ViewN/AView Earnings Details
6/15/2015Q2 2015($0.27)($0.52)ViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
9/9/2014Q3 2014($0.25)($0.30)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
3/17/2014Q1 2014($0.25)($0.37)ViewN/AView Earnings Details
1/29/2014Q4 2013($0.25)($0.97)ViewN/AView Earnings Details
9/16/2013Q3 2013($0.86)($0.37)ViewN/AView Earnings Details
6/14/2013Q2 2013($1.25)($156.25)ViewN/AView Earnings Details
3/25/2013Q1 2013($107.50)($206.25)ViewN/AView Earnings Details
2/13/2013Q4 2010($67.50)ViewN/AView Earnings Details
9/12/2011Q3 2011($1.00)ViewN/AView Earnings Details
6/14/2011Q2 2011($2.38)ViewN/AView Earnings Details
3/17/2011Q1 2011($2.50)ViewN/AView Earnings Details
6/3/2010Q2 2010($3.13)ViewN/AView Earnings Details
2/19/2010Q4 2009$1.50ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Advaxis (NASDAQ:ADXS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.36 EPS
Next Year EPS Consensus Estimate: $-2.44 EPS

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 37.39%
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ ADXS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2018Anthony A LombardoCEOSell32$2.93$93.7692,903View SEC Filing  
1/3/2018Sara BonsteinCFOSell5,224$3.18$16,612.32229,237View SEC Filing  
11/6/2017Robert PetitInsiderSell3,723$3.30$12,285.90220,917View SEC Filing  
11/6/2017Sara BonsteinCFOSell3,862$3.30$12,744.60227,908View SEC Filing  
11/2/2017Anthony A LombardoCEOSell24$3.19$76.5692,935View SEC Filing  
11/2/2017Robert PetitInsiderSell12,625$3.19$40,273.75237,265View SEC Filing  
11/2/2017Sara BonsteinCFOSell12,734$3.19$40,621.46244,504View SEC Filing  
10/11/2017Adage Capital Partners Gp, L.LMajor ShareholderSell600,000$4.30$2,580,000.00View SEC Filing  
9/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,239,323$4.42$5,477,807.66View SEC Filing  
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96122,051View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40131,963View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.2869,804View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80303,127View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04123,659View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26103,087View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.0891,759View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.0066,430View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.0082,120View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87316,661View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35128,025View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25131,164View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.0086,220View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.4679,980View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84313,394View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12130,557View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53119,821View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88165,932View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Advaxis (NASDAQ ADXS) News Headlines

Source:
DateHeadline
The No BS Plan: Week 2 Report - The Advaxis Apocalypse Is Nigh?The No BS Plan: Week 2 Report - The Advaxis Apocalypse Is Nigh?
seekingalpha.com - February 25 at 9:48 AM
Advaxis (ADXS) Prices 10M Offering of Common Stock at $2/ShareAdvaxis (ADXS) Prices 10M Offering of Common Stock at $2/Share
www.streetinsider.com - February 22 at 4:47 PM
Advaxis Prices $20.0 Million Public Offering of Common StockAdvaxis Prices $20.0 Million Public Offering of Common Stock
finance.yahoo.com - February 22 at 4:47 PM
Advaxis looks to raise $20 million via share offeringAdvaxis looks to raise $20 million via share offering
finance.yahoo.com - February 22 at 4:47 PM
BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31
www.reuters.com - February 22 at 9:12 AM
Advaxis (ADXS) Plans Offering of Common StockAdvaxis (ADXS) Plans Offering of Common Stock
www.streetinsider.com - February 22 at 9:12 AM
Advaxis Announces Proposed Public Offering of Common StockAdvaxis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 21 at 4:45 PM
Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical Cancer in EUAdvaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical Cancer in EU
www.streetinsider.com - February 15 at 4:46 PM
3 Things In Biotech You Should Learn Today: February 13, 20183 Things In Biotech You Should Learn Today: February 13, 2018
seekingalpha.com - February 15 at 4:46 PM
Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical ... - StreetInsider.comAdvaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical ... - StreetInsider.com
www.streetinsider.com - February 14 at 3:26 PM
Advaxis Takes Its First Step Towards Regulatory Approval - Seeking AlphaAdvaxis Takes Its First Step Towards Regulatory Approval - Seeking Alpha
seekingalpha.com - February 14 at 3:26 PM
Advaxis (ADXS) Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for Treatment of ... - StreetInsider.comAdvaxis (ADXS) Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for Treatment of ... - StreetInsider.com
www.streetinsider.com - February 12 at 3:24 PM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological CancerAdvaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
finance.yahoo.com - February 12 at 3:24 PM
$3.03 Million in Sales Expected for Advaxis, Inc. (ADXS) This Quarter$3.03 Million in Sales Expected for Advaxis, Inc. (ADXS) This Quarter
www.americanbankingnews.com - February 11 at 4:30 AM
-$0.58 EPS Expected for Advaxis, Inc. (ADXS) This Quarter-$0.58 EPS Expected for Advaxis, Inc. (ADXS) This Quarter
www.americanbankingnews.com - February 9 at 2:34 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer ImmunotherapiesData Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
finance.yahoo.com - January 29 at 3:25 PM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation OncologyAdvaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
finance.yahoo.com - January 25 at 3:25 PM
Advaxis, Inc. (ADXS) Expected to Post Quarterly Sales of $3.03 MillionAdvaxis, Inc. (ADXS) Expected to Post Quarterly Sales of $3.03 Million
www.americanbankingnews.com - January 25 at 4:22 AM
TG Therapeutics (TGTX) and Advaxis (ADXS) Financial ContrastTG Therapeutics (TGTX) and Advaxis (ADXS) Financial Contrast
www.americanbankingnews.com - January 24 at 3:26 AM
-$0.58 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter-$0.58 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter
www.americanbankingnews.com - January 23 at 3:10 PM
Zacks: Analysts Anticipate Advaxis, Inc. (ADXS) Will Announce Earnings of -$0.58 Per ShareZacks: Analysts Anticipate Advaxis, Inc. (ADXS) Will Announce Earnings of -$0.58 Per Share
www.americanbankingnews.com - January 6 at 11:26 AM
Sara Bonstein Sells 5,224 Shares of Advaxis, Inc. (ADXS) StockSara Bonstein Sells 5,224 Shares of Advaxis, Inc. (ADXS) Stock
www.americanbankingnews.com - January 3 at 7:54 PM
Pre-Market Technical Scan on Biotech Equities -- Grifols, Advaxis, Nektar Therapeutics, and Spark TherapeuticsPre-Market Technical Scan on Biotech Equities -- Grifols, Advaxis, Nektar Therapeutics, and Spark Therapeutics
www.prnewswire.com - January 3 at 10:50 AM
Advaxis, Inc. (ADXS) to Post FY2018 Earnings of ($2.28) Per Share, Cantor Fitzgerald ForecastsAdvaxis, Inc. (ADXS) to Post FY2018 Earnings of ($2.28) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - December 30 at 10:02 PM
Cantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price TargetCantor Fitzgerald Analysts Give Advaxis (ADXS) a $19.00 Price Target
www.americanbankingnews.com - December 29 at 5:04 PM
ETFs with exposure to Advaxis, Inc. : December 27, 2017ETFs with exposure to Advaxis, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 12:48 PM
HC Wainwright Reiterates "$23.00" Price Target for Advaxis (ADXS)HC Wainwright Reiterates "$23.00" Price Target for Advaxis (ADXS)
www.americanbankingnews.com - December 27 at 8:48 AM
Advaxis, Inc. :ADXS-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017Advaxis, Inc. :ADXS-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 11:54 AM
Advaxis, Inc. (ADXS) Expected to Post FY2019 Earnings of ($2.45) Per ShareAdvaxis, Inc. (ADXS) Expected to Post FY2019 Earnings of ($2.45) Per Share
www.americanbankingnews.com - December 25 at 4:40 PM
Advaxis, Inc. (ADXS) Expected to Earn FY2022 Earnings of $3.12 Per ShareAdvaxis, Inc. (ADXS) Expected to Earn FY2022 Earnings of $3.12 Per Share
www.americanbankingnews.com - December 22 at 9:22 PM
Cantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis (ADXS)Cantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis (ADXS)
www.americanbankingnews.com - December 22 at 6:12 PM
Advaxis 2018: A New Year, A New Hope - Seeking AlphaAdvaxis 2018: A New Year, A New Hope - Seeking Alpha
seekingalpha.com - December 22 at 11:34 AM
Edited Transcript of ADXS earnings conference call or presentation 21-Dec-17 3:00pm GMTEdited Transcript of ADXS earnings conference call or presentation 21-Dec-17 3:00pm GMT
finance.yahoo.com - December 22 at 11:34 AM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business UpdateAdvaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update
finance.yahoo.com - December 21 at 11:28 AM
Does Advaxis Inc’s (NASDAQ:ADXS) -20.1% EPS Decline Reflect A Long-Term Trend?Does Advaxis Inc’s (NASDAQ:ADXS) -20.1% EPS Decline Reflect A Long-Term Trend?
finance.yahoo.com - December 20 at 11:27 AM
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017
finance.yahoo.com - December 14 at 11:34 AM
Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates?Is Advaxis Inc (NASDAQ:ADXS) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - December 14 at 11:34 AM
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma - PR Newswire (press release)
www.prnewswire.com - November 27 at 7:55 AM
Reviewing Advaxis (ADXS) and Its PeersReviewing Advaxis (ADXS) and Its Peers
www.americanbankingnews.com - November 27 at 3:18 AM
Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - November 22 at 4:08 PM
Advaxis to Present at the Jefferies 2017 London Healthcare Conference - Business Wire (press release)Advaxis to Present at the Jefferies 2017 London Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 9 at 9:36 PM
Advaxis to Present at the Jefferies 2017 London Healthcare ConferenceAdvaxis to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 4:28 PM
Advaxis (ADXS) "Buy" Rating Reaffirmed at HC WainwrightAdvaxis' (ADXS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 8 at 11:10 PM
Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 3,862 SharesAdvaxis, Inc. (ADXS) CFO Sara Bonstein Sells 3,862 Shares
www.americanbankingnews.com - November 6 at 8:23 PM
Advaxis, Inc. (ADXS) Insider Robert Petit Sells 3,723 SharesAdvaxis, Inc. (ADXS) Insider Robert Petit Sells 3,723 Shares
www.americanbankingnews.com - November 6 at 8:22 PM
Advaxis, Inc. (ADXS) Insider Robert Petit Sells 12,625 SharesAdvaxis, Inc. (ADXS) Insider Robert Petit Sells 12,625 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 SharesAdvaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program - Business Wire (press release)Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program - Business Wire (press release)
www.businesswire.com - November 1 at 3:49 PM
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL ProgramAdvaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program
finance.yahoo.com - November 1 at 3:49 PM
Advaxis: So Its Panic, Then? Where This Thing Is Headed - Seeking AlphaAdvaxis: So It's Panic, Then? Where This Thing Is Headed - Seeking Alpha
seekingalpha.com - October 30 at 3:56 PM

SEC Filings

Advaxis (NASDAQ:ADXS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Advaxis (NASDAQ ADXS) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.